GlassScriptPhysician profile
Marc K Taormina
NPI 1992788038
$55,086.68
in general payments reported to CMS, 2019-2025
50 companies · $2,112 in 2025
The $2,112 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,078 · 2020: $1,517 · 2021: $4,593 · 2022: $14K · 2023: $4,031 · 2024: $26K · 2025: $2,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $17K · Food and Beverage: $11K · Consulting Fee: $3,990 · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $17,382.40 |
| Food and Beverage | $10,716.28 |
| Consulting Fee | $3,990.00 |
| Education | $325.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $22,265.83 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| E.R. Squibb & Sons, L.L.C. | $12,194.69 | 2021-2023 | Zeposia |
| Abbvie INC. | $4,209.79 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $2,492.83 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,995.00 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,956.69 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $1,609.20 | 2019-2025 | |
| Celgene Corporation | $1,509.84 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $909.12 | 2024-2025 | Omvoh, Zepbound |
| Intercept Pharmaceuticals, INC. | $744.06 | 2019-2025 | Ocaliva |
| Qol Medical, LLC | $720.03 | 2021-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $625.96 | 2019-2024 | Dificid, Zinplava |
| Daiichi Sankyo INC. | $450.97 | 2019-2024 | Injectafer |
| Amgen INC. | $331.29 | 2020-2025 | Amjevita, Avsola, Uplizna |
| Regeneron Healthcare Solutions, INC. | $322.80 | 2022-2025 | Dupixent |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Taormina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.